In recent years, novel autologous chimeric antigen receptor-modified T cell (CAR-T) therapies targeting the B-cell lineage antigen, CD19, emerged as a new hope for B-ALL patients with limited treatment options [10]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.